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Abstract
BACKGROUND: Preliminary very encouraging clinical results of intensity modulated radiation therapy
(IMRT) in Head Neck Cancer (HNC) are available from several large centers. Tumor control rates seem
to be kept at least at the level of conventional three-dimensional radiation therapy; the benefit of normal
tissue preservation with IMRT is proven for salivary function. There is still only limited experience with
IMRT using simultaneously integrated boost (SIB-IMRT) in the head and neck region in terms of
normal tissue response.The aim of this work was (1) to establish tumor response in HNC patients treated
with SIB-IMRT, and (2) to assess tissue tolerance following different SIB-IMRT schedules. RESULTS:
Between 1/2002 and 12/2004, 115 HNC patients have been curatively treated with IMRT. 70% received
definitive IMRT (dIMRT), 30% were postoperatively irradiated. In 78% concomitant chemotherapy was
given. SIB radiation schedules with 5-6 x 2 Gy/week to 60-70 Gy, 5 x 2.2 Gy/week to 66-68.2 Gy
(according to the RTOG protocol H-0022), or 5 x 2.11 Gy/week to 69.6 Gy were used. After mean 18
months (10-44), 77% of patients were alive with no disease. Actuarial 2-year local, nodal, and distant
disease free survival was 77%, 87%, and 78%, respectively. 10% were alive with disease, 10% died of
disease. 20/21 locoregional failures occurred inside the high dose area. Mean tumor volume was
significantly larger in locally failed (63 cc) vs controlled tumors (32 cc, p <0.01), and in definitive (43
cc) vs postoperative IMRT (25 cc, p <0.05); the locoregional failure rate was twofold higher in
definitively irradiated patients. Acute reactions were mild to moderate and limited to the boost area, the
persisting grade 3/4 late toxicity rate was low with 6%. The two grade 4 reactions (dysphagia, laryngeal
fibrosis) were observed following the SIB schedule with 2.2 Gy per session. CONCLUSION:
SIB-IMRT in HNC using 2.0, 2.11 or 2.2 Gy per session is highly effective and safe with respect to
tumor response and tolerance. SIB with 2.2 Gy is not recommended for large tumors involving laryngeal
structures.
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Abstract
Background: Preliminary very encouraging clinical results of intensity modulated radiation
therapy (IMRT) in Head Neck Cancer (HNC) are available from several large centers. Tumor
control rates seem to be kept at least at the level of conventional three-dimensional radiation
therapy; the benefit of normal tissue preservation with IMRT is proven for salivary function. There
is still only limited experience with IMRT using simultaneously integrated boost (SIB-IMRT) in the
head and neck region in terms of normal tissue response.
The aim of this work was (1) to establish tumor response in HNC patients treated with SIB-IMRT,
and (2) to assess tissue tolerance following different SIB-IMRT schedules.
Results: Between 1/2002 and 12/2004, 115 HNC patients have been curatively treated with IMRT.
70% received definitive IMRT (dIMRT), 30% were postoperatively irradiated. In 78% concomitant
chemotherapy was given.
SIB radiation schedules with 5–6 × 2 Gy/week to 60–70 Gy, 5 × 2.2 Gy/week to 66–68.2 Gy
(according to the RTOG protocol H-0022), or 5 × 2.11 Gy/week to 69.6 Gy were used.
After mean 18 months (10–44), 77% of patients were alive with no disease. Actuarial 2-year local,
nodal, and distant disease free survival was 77%, 87%, and 78%, respectively. 10% were alive with
disease, 10% died of disease. 20/21 locoregional failures occurred inside the high dose area. Mean
tumor volume was significantly larger in locally failed (63 cc) vs controlled tumors (32 cc, p <0.01),
and in definitive (43 cc) vs postoperative IMRT (25 cc, p <0.05); the locoregional failure rate was
twofold higher in definitively irradiated patients.
Acute reactions were mild to moderate and limited to the boost area, the persisting grade 3/4 late
toxicity rate was low with 6%. The two grade 4 reactions (dysphagia, laryngeal fibrosis) were
observed following the SIB schedule with 2.2 Gy per session.
Conclusion: SIB-IMRT in HNC using 2.0, 2.11 or 2.2 Gy per session is highly effective and safe
with respect to tumor response and tolerance. SIB with 2.2 Gy is not recommended for large
tumors involving laryngeal structures.
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Preliminary very encouraging clinical results of IMRT in
HNC are available from several large centers [1-6]. Tumor
control rates seem to be kept at least at the level of conven-
tional three-dimensional radiation therapy (3DCRT); the
benefit of normal tissue preservation with IMRT is proven
for salivary function; reduced dose exposure of the man-
dibular bone is described (manuscript submitted).
There is still only limited experience with simultaneously
integrated boost (SIB) application in the head and neck
region in terms of normal tissue response. As known from
3DCRT, dose, fractionation and treated volumes are the
tumor control and normal tissue tolerance defining
parameters. Dosimetric and volumetric relationships
need to be newly defined for SIB, as the radiobiological
response of intermediate dose volumes encompassing rel-
atively small high-dose areas with increased doses per
fraction seems to substantially differ from the situation in
conventional techniques.
The intention of this prospective study was to present 3-
year experiences in SIB-IMRT of HNC patients, focused on
tumor response and tissue tolerance following different
SIB schedules.
Results
115 of 310 head and neck carcinoma (HNC) patients
referred to our radiation oncology institution were treated
curatively with IMRT (nasopharyngeal tumors excluded
from analysis). The analysed patients were irradiated
between January 2002 and December 2004; the mean fol-
low up time was 18 months (10 – 44).
The median age was 60 years (15 – 85), with a male to
female ratio of 3.4 : 1 (89 men, 26 women). The WHO
Performance Status was 0 in 87, 1 in 26, and 2 in two
patients. 71 patients (62 %) of the entire cohort presented
with a T3/4 or T1-2/N2c, N3 tumor, 13 individuals (11 %)
were referred for radiation of a recurrent tumor. Tumor
subsites are listed in Table 1. The TN distribution con-
sisted of 9 % T1, 28 % T2, 52 % T3/4 stages, and 11 %
recurrent situations, respectively. 23 % of all patients pre-
sented with a N2c/3 nodal stage.
The specific aims for performing IMRT were parotid gland
sparing (n ~100), and/or mandible bone sparing (n = 76)
and/or anterior visual pathway and/or brain sparing (n =
10).
34 patients (30 %, 30 following an R1 resection) were
treated in a postoperative setting, 80 patients (70 %)
underwent a primarily definitive radiation, re-irradiation
after high dose 3DCRT was performed in one patient. One
patient received preoperative irradiation.
Concomitant cisplatin based weekly chemotherapy (40
mg/m2, once a week, 1–7 cycles) was given to 89 patients
(77 %). 61/89 patients (69 %) received 5 – 7 cycles
(depending on the fractionation regime); 18 (20 %)
underwent 4 cycles, 10 (11 %) only tolerated between 1 –
3 cycles. No treatment interruption was related to actinic
toxicity; total treatment time was mean 46 days (33 – 60).
Tumor response and survival
Actuarial 2-year local, nodal and distant disease free sur-
vival was 77, 87 and 78 %, respectively (Figures 1- 5). At
the time of data analysis (November 2005), 88/115
patients were alive with no evidence of disease (ANED, 77
%), 11 patients were alive with local and/or distant dis-
ease (AD, 10 %). 12/14 patients died of disease (DOD, 10
%), two died with intercurrent disease.
21/115 patients (18 %) experienced loco-regional failure
(recurrence in 13, tumor persistence in 8, Table 2). 12/13
recurrences developed inside PTV1 ('in field', covered by
> 95 % PTD), in one case marginal recurrence occurred in
the distal, cervical aspect of the initial tumor arising from
the floor of the mouth. No failure occurred related to/in
the adjacent tissue of spared parotid gland.
In loco-regionally failed cases, doses < 95 % were deliv-
ered to mean 13.5 % (0 – 50) of PTV1, vs mean ~8 % (0 –
24) in loco-regionally controlled individuals (p > 0.5,
Table 1: Diagnoses and related primary tumor (T) stage distribution in 115 IMRT patients.
Recurrence T1 T2 T3 T4 Total
Oropharynx 3 7 16 16 14 56
Oral cavity 5 2 5 2 5 19
Hypopharynx 0 1 6 4 5 16
PNS 2 0 0 0 10 12
Supraglottic 0 0 5 1 1 7
Others 3 0 0 1 0 5
Total 13 10 32 24 36 115
PNS: paranasal sinus tumors others: thyroid (2), glottic (1), orbital (1) and parotid gland (1) tumorsPage 2 of 15
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from distant failure.
Local failure occurred twice as often in definitively as in
postoperatively irradiated patients, with 15/80 (19 %) vs
3/34 (9 %) (Figure 5), respectively; nodal failure rate was
11/80 (14 %), vs 1/34 (3 %) distant failure rate 6/80 (8
%) vs 4/34 (12 %), respectively. Tumor volumes in the
definitive vs postoperative IMRT subgroup differed signif-
icantly with mean/median 43/32 cc (3 – 205) vs 24.7/14
cc (2 – 74), respectively (p < 0.05).
The primary GTV measured mean 38.2 cc (2 – 206), the
nodal GTV mean 12 cc (1 – 70). The mean volume of the
primary GTV in patients who failed locally was 63 cc (13
– 206) and differed significantly from mean 32 cc (range
2 – 124) in locally controlled patients (p < 0.01, Table 3).
Early toxicity
Xerostomia grade 3 was observed in 10 % of patients at
completion of treatment. Mucositis (15 % grade 3), and
dermatitis (5 % grade 3) were limited to the high dose vol-
ume. Grade 3 dysphagia developed in only 20 % of the
cases, translating into an improved patient's performance
status during treatment (QoL analysis in preparation). No
grade 4 early reaction, and no radiation-toxicity related
treatment interruption occurred.
A gastric feeding tube was used in 37 patients (33 %), in
the majority of them prior to IMRT start because of pre-
treatment weight loss due to pain or tumor-related
mechanic dysphagia. The mean weight loss at completion
of IMRT was 6 % (range: 25 % loss to 15 % gain under
treatment); 19/113 patients (17 %) lost ≥ 10 % of their
initial weight; one third of them despite feeding tube (>10
% loss in 20 % of patients of whom feeding tube was
inserted in 33 %). 42 % of all patients kept pre-treatment
weight (n = 45) or gained weight under treatment (n = 8).
Subacute and late toxicity (> 90 days from treatment 
completion)
19 (18 %) grade 3/4 subacute or late effects (included 2
cases with a grade 3 xerostomia) in 18 out of 109 individ-
uals treated with SIB-IMRT, were observed so far (Table 4);
all lesions were localized in the high dose SIB area (PTV1,
mean 176 cc, range 78 – 299), and developed 2 – 12
months after SIB-IMRT completion. This includes a dys-
phagia grade 4, a laryngeal fibrosis grade 4 requiring a per-
manent tracheostoma, an osteo-radionecrosis grade 3 of
the mandible, which was resolved by lingual bone decor-
tication, grade 3 dysphagia in 2 cases, grade 3 xerostomia
1 year after IMRT in 2 (in one of them no parotid gland
sparing was performed), and mucosal ulcers in 12 cases.
The most frequent grade 3/4 late term effect was mucosal
ulceration in the area of the SIB. This was characterized by
its appearance mean 4 months (2 – 6) after IMRT comple-
tion, by its persistence for mean 3 months (1 – 7), and
spontaneous healing in all locally controlled cases. All
ulcers occurred in oro-hypopharyngeal and oral cavity
tumor patients, no ulcer was observed in paranasal sinus
or nasopharyngeal cancer patients. In 3 patients who suf-
fered from persisting ulceration for a period longer than 7
months, underlying tumor persistence was histologically
confirmed 8, 10 and 11 months after completion of treat-
ment. One of these three patients experienced substantial
ulcer bleeding from the large tumor ulceration which was
already present before IMRT start.
Actuarial 2 year local, nodal, and distant disease free survival: 77 %, 87 %, and 78 %, respectivelyFig re 1
Actuarial 2 year local, nodal, and distant disease free survival: 
77 %, 87 %, and 78 %, respectively Actuarial 2 year local disease free survival in different HNC entitiesFig re 2
Actuarial 2 year local disease free survival in different HNC 
entities. Hypopharyngeal tumors revealed the highest local 
control rates, while oral cavity tumors showed the lowest 
rate. This fact can not be explained by TN stages or tumor 
volumes, and is issue of further data anaylses.
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%, or 0 – 7.7 cc) of the entire PTV1 received more than
110 % of the prescribed total dose. In 9 of the 19 cases,
maximal doses were below 110 %; in only 4/19 patients,
a hot spot area was matching with the area of a grade 3/4
tissue lesion.
The patient with grade 4 laryngeal fibrosis became symp-
tomatic after a latency of 12 months following treatment
with SIB 2.2 to 66 Gy for a large T4 hypopharyngeal cancer
that involved the oropharynx, hypopharynx and larynx.
No hot spot was delivered to the area of the actinic lesion.
3.5 years post treatment, this patient is free of disease.
The 3 patients with grade 3/4 dysphagia were treated for
extended T3 primaries of the hypopharynx (2) and
oropharynx (1); all three affected patients are women.
After follow up periods of 9 and 14 months, no improve-
ment was observed in two; a third patient was lost of fol-
low up 9 months after treatment completion.
SIB-IMRT resulted in a 1-year swallowing / salivary func-
tion of grade 0 -1 dysphagia / xerostomia in 95 / 80 % (n
= 77). In only 2 patients, less than 30 % of the total
parotid gland volume (both parotid glands = 100 % vol-
ume) could be kept below mean doses of 26 Gy; in 74 %
of the patients the spared glandular total volume ranged
between 60 % and 100 %, in ~25 % of the patients, the
protected glandular volume ranged between 30 and 60 %
(Figure 7 and Figure 8 illustrate an example of spared total
parotid gland volume of 62 %).
When late reactions are analysed according to the differ-
ent SIB schedules, the following distribution was found: 7
events developed in the 33 SIB 2.2 cases (21 %), 10 events
in the 47 SIB 2.11 (21 %), and 2 in the 22 of 29 SIB 2.0
patients (9 %) with doses > 65 Gy.
In locally controlled patients, 6 persistent late effects were
observed: xerostomia (2), laryngeal fibrosis (1), and dys-
phagia (3), last assessed at 14 months, 3.5 years, and 9 –
17 months after completion of IMRT, respectively. This
translates into a grade 3/4 toxicity rate of ~6 % (5/80) in
the SIB2.11/2.2 subgroup, or of 5.5 % (6/109) in the entire
SIB-IMRT cohort, respectively.
At one year post treatment, mean weight loss was 4 %
(range minus 24 % to plus 13 % of pre-treatment value);
7/77 patients with 1 year follow up still had ≥ 10 % less
weight than before treatment, 18 patients reached their
initial weight or more (n = 10).
Discussion
Disease control
The high 2-year locoregional disease free survival as well
as the locoregional failuare pattern in our patients is com-
parable to the excellent results reported in the literature
on IMRT of head and neck tumors (Table 5). Most of these
results are superior to historic results following 3DCRT
series with disease free survival rates ranging between
about 40 and 88 % [4,7].
Actuarial 2 year local disease free survival according to the T-stagesFig r  3
Actuarial 2 year local disease free survival according to the 
T-stages.
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Table 3: Volumetric characteristics of loco-regionally failed (LRF) vs loco-regionally controlled (LRC) patients without vs with late 
term reactions grade 3/4.
LRF LRC, G 0–2 LRC, G 3–4
n 21 77 14*
GTV PT (cc) 63 32 31.4
GTV LN (cc) 8.5 15 13
PTV1 (cc) 174 154 176
% PTV1 >110 % 0.8 0.8 1.3
% PTV1 < 95 % 13.5 8.3 8.0
Gross tumor volume (GTV) in LRF patients was significantly larger than in controlled LRC individuals (p < 0.01). Isodose comparison showed PTV1 
in controlled patients tendentially better covered, with less volumes getting doses < 95 %, compared with failed patients.
* : the 2 patients with xerostomia grade 3 and the 3 patients with ulcers related to tumor persistence were excluded from this analysis.Page 4 of 15
(page number not for citation purposes)
Radiation Oncology 2006, 1:7 http://www.ro-journal.com/content/1/1/7Operated patients in our cohort showed half as large
tumors and half the local recurrence rate as primarily irra-
diated patients. The significant correlation between tumor
size and tumor control is shown by several investigators
[8,9].
Dawson et al reported on 12/58 failed patients (21 %), of
whom 10 /12 relapsed in-field, two marginally [1]. Of 17/
126 (13 %) failures in Chao's et al's series [5], 9 were
inside the CTV1, one was marginal, one outside the CTV1
but inside CTV2.
Considering own and published results on locoregional
failure analyses [1,5,10,11], one can conclude that the
volumetric concept used so far in HNC IMRT is appropri-
ate, and the loco-regional control can hardly be improved
by volumetric optimisation.
Acute tolerance
Grade 3 mucositis, dermatitis, and dysphagia rates were
15 %, 5 %, and 20 %, respectively, comparing with 50 %
to more than 80 % acute mucositis [12-15], and ~33 % up
to 50 – 70 % dysphagia [7,15,16] in 3DCRT.
De Arruda et al reported 38 % grade 3 mucositis in 50 SIB-
IMRT patients, and 6 % grade 3 skin reactions; 62 % devel-
oped grade 3 acute reactions [17]. Chao et al [4] found 37
% grade 3/4 skin toxicity, 40 % grade 3/4 mucositis in 74
oropharyngeal cancer patients necessitating a gastrostomy
tube during chemo-IMRT in 23 %.
Mucosal and dermal acute reactions occurred only local-
ized and healed up faster in our IMRT patients than used
in 3DCRT patients. Only few patients presented with an
acute grade 3 mucositis in the boost area. This phenome-
non is not entirely understood and may be related to
improved tissue tolerance when only moderate doses are
delivered to adjacent tissue areas.
Late tolerance
12 subacute grade 3/4 mucosal ulcers in the PTV1 were
observed, which were characterized by self-limitation and
spontaneous healing. 8/19 patients with late reactions
were exposed to > 110 % of prescribed total doses, in only
4 of them hot spots matched with the area of the actinic
lesion, indicating the hot spots not to be the main reason
for these lesions.
Xerostomia grade 3 at 1 year was scored in 2 (3 %)
patients at risk; 3 patients at risk developed dysphagia
grade 3/4. In a group of 50 patients, De Arruda et al
observed 8 cases (16 %) of pharyngeal grade 3 reactions
in the MSKCC IMRT series; three patients developed cervi-
cal esophageal stricture requiring dilatations [17]. In a
3DCRT study by Huguenin et al [7], higher incidences of
12 % and 22 % were reported for xerostomia and dys-
phagia, respectively. Dysphagia/aspiration related struc-
tures have been investigated by Eisbruch et al [18].
Pharyngeal constrictors, glottis and supraglottic larynx
have been identified as the anatomic correlates whose
damage may cause the symptoms. IMRT can moderately
spare these structures; if substantially affected by tumor,
hot spots and probably also SIB doses > of 2.0 Gy per frac-
tion should be avoided. Consequently, we avoid SIB2.2/2.11
in patients where the tumor affects major parts of the lar-
ynx.
In ~75 patients at risk, one grade 3 osteonecrosis, treated
without mandible resection, was diagnosed 4 months
after IMRT completion. In 3DCRT, the incidence of osteo-
Actuarial 2 year local disease free survival in definitively vs postoperativ ly irradiated patients (non-sig ificant differ-ence)Fig re 5
Actuarial 2 year local disease free survival in definitively vs 
postoperatively irradiated patients (non-significant differ-
ence).
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Radiation Oncology 2006, 1:7 http://www.ro-journal.com/content/1/1/7radionecrosis is higher by approximately 4–6 % after 2
years [19], although FU of the presented IMRT cohort is
still short for definitive result.
SIB-IMRT
The advantage of SIB-IMRT consists in a better target con-
formity [20-24], less dose to critical structures, moderate
treatment acceleration with reduced total treatment time,
and the option of dose escalation in the gross tumor vol-
ume.
There is limited experience in normal tissue tolerance fol-
lowing SIB-IMRT in HNC.
Many different SIB schedules (references [2,17,22-29],
two RTOG protocols (H-0022 and 0225)) have been pub-
lished; to this date there is no universally agreed standard
of dosage.
We found SIB 2.11 and SIB2.2 equally well tolerated and safe
with respect to acute and late normal tissue tolerance
compared to 3DCRT, except of the described grade 4 reac-
tions when 2.2 Gy per session delivered to larger laryngeal
areas. The weakness of this comparison lies in its retro-
spective approach.
The unexpected observation of very few (~15 %) cases
with grade 3 acute mucositis despite full SIB dose deliv-
ered to the mucosa, and observed better tissue healing, are
interesting and clinically relevant findings that may indi-
cate a higher tolerance, when surrounding tissue volumes
are exposed to lower doses. This phenomenon has been
described decades ago, based on the clinical observation
of the so called 'grid therapy' [30-34], a technique used to
deliver high single fraction doses of radiation by convert-
ing a large treatment field into many smaller fields. The
use of this technique goes back to the beginning of the last
century when orthovoltage radiation was mainly used for
external beam radiation therapy. Small areas of skin
within an irradiated field, shielded from direct radiation,
are reported to serve as centers for re-growth of normal
skin tissue, and allowed up to six times the conventional
open doses without an increase in skin reactions or com-
plications to underlying structures.
Moreover, grade 3/4 late effects could not be related to hot
spots in the majority of our cases, indicating additional
factors determining normal tissue tolerance in IMRT.
With respect to future proceeding, mild dose escalation
limited to the GTV in patients with intermediate tumor
Table 2: Characteristics on 21 patients (18 %) with loco-regional failure (LRF) are listed; patients with isolated distant failure (DF) are 
not included in this list. Mean time to failure (TTF) was 5 – 6 months in recurred patients; in 8 individuals (1/3) tumor persistence was 
observed.
Number Diagnosis TNM LRF DF Outcome TTF (m) GTV 
PT (cc)
GTV 
LN (cc)
PTV1 
(cc)
%PTV <95 %PTV < 93%
1 OC T4N2c LRR AD 4 15 3 127 9 5
2 OC T4N2c LRR DOD 10 75 27 253 6 3
3 OC T1N2b LR distant DOD 3 na 6.5 74 5 2
4 OC T3N2c LR DOD 15 23 1 144 14 9
5 OC T2N1 LR AD 4 45 2 124 5 2
6 OC Recurrence LRR AD 0 71 6 117 25 17
7 OC T2N0 Persistence AD 0 13 0 64 0 0
8 OC T2N2c Persistence AD 0 16 2.4 82 50 7
9 OC T4N1 Persistence DOD 0 206 5 270 4 1
10 oro T4N2b LR distant AD 13 100 2 255 8 4
11 oro T4N2c NR distant DOD 3 34 15 179 8 4
12 oro T4N0 Persistence DOD 0 57 0 188 5 2
13 oro T3N2b Persistence distant AD 0 97 5 393 14 5
14 oro T3N2a Persistence AD 0 31 4.3 198 35 25
15 oro T4N2b LRR AD 8 41 5 178 15 10
16 Sinus T4N0 Persistence DOD 10 75 0 75 8 5
17 Sinus Recurrence Persistence distant AD 0 56 20 89 27 11
18 Sinus T4N2b LRR DOD 15 141 17 176 11 5
19 Glottic Recurrence NR distant DOD 13 9 118 8 3 3
20 Supragl T4N2c LRR distant AD 6 79 18 353 7 2
21 Hypoph T3N2c NR ANED * 9 22 30 210 15 7
Mean 5.4 63.0 8.5 174.6 13.3 6.1
Range 0 – 21 9 – 206 0 – 99 64 – 353 0 – 50 0 – 25
LRF loco-regional failure; DF distant failure; LC local recurrence; LRR loco-regional recurrence; NR nodal recurrence; TTF time to failure; GTVPT 
primary gross tumor volume, GTV LN lymph node gross tumor volume; PTV1 planning target volume 1 (boost).Page 6 of 15
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Table 4: Characteristics on patients with grade 3/4 late term effects (19 events in 18 patients). In all cases with grade 3/4 ulcers not healing during a 6 months period (n = 3, grey 
bars), ulcer persistence was found basing on tumor persistence (No 3,13, 16; data from these patient as well as of the 2 individuals with grade 3 xerostomia were excluded from 
this volumetric analysis (EA) of the 14 patients with grade 3/4 lesions).
Outcome
No. Dg TNM Sequence Grade 3/4 t post RT (m) Duration (m) Treatment NTR Tumor PTD d/f SIB Dmax G3/4 GTV PT 
(cc)
PTV1 (cc) cc>110% 
D
1 Cent oro T3N2c Prim Ulcer 4 7 - Healed ANED 66/54 2.2 75.7 56 213 0
2 Supragl T2N2b Prim Ulcer 6 1 - Healed ANED 69.6/54 2.11 75.9 20.8 162.5 0
3 Oral cav T2N0 Postop Ulcer 3 4 0 Healed ANED 66/54 2 80.7 14 81.7 1.6
4 Hypo T4N1 Prim Ulcer 3 3 HBO Healed ANED 66/54 2.2 75.8 74 299 0
5 " " " Larynx fibrosis 10 Persistent 
(30)
Tracheostoma Tracheostoma ANED " 2.2 75.8 " " 0
6 Hypo T2N2b Prim Ulcer 4 5 - Healed ANED 69.6/54 2.11 74.8 27 145 0
7 Cent oro T3N2b Prim Ulcer 6 1 - Healed ANED 66/54 2.2 77.3 30 201 2
8 Hypo T2N2b Prim Ulcer 6 2 - Healed ANED 69.6/54 2.11 76.8 34.5 220 2.2
9 Cent oro T3N0 Prim Ulcer 4 3 HBO Healed ANED 66/54 2.2 77.3 29 77.7 7.7
10 Lat oro T3N2b Postop Ulcer 2 3 - Healed ANED 65.4/54 2.11 72.8 7.8 212 0
11 Cent oro T3N2b Prim Bone 4 6 Surgery Healed ANED 66/54 2.2 76.5 37.5 208 2
12 Hypo T3N0 Prim Dysphagia 2 ? (8) Dilatation Persistent ANED 69.6/54 2.11 75.7 32 149.5 0
13 Hypo T3N2c Prim Dysphagia 5 Persistent 
(14)
Dilatation Persistent ANED 68.2/54 2.2 79.2 21.5 210 2.1
14 Cent oro T3N2b Prim Dysphagia 5 ? (9, lost) - ? ANED 69.6/54 2.11 76.7 24 113 0
15 Oral cav T2N2c Prim Ulcer 3 Persistent - Persistent TU 
Persistent
69.6/54 2.11 EA EA EA EA
16 Lat oro T2N1 Prim Ulcer 2 Persistent - Persistent TU 
Persistent
69.6/54 2.11 EA EA EA EA
17 Cent oro T3N2b Prim Bleeding 
ulcer
0 Persistent Surgery Persistent TU 
Persistent
69.6/54 2.11 EA EA EA EA
18 Hypo T4N2a Prim Xerostomia 0 Persistent 
(14)
- Persistent ANED 69.6/54 2.11 EA EA EA EA
19 Cent oro T1N2b postop Xerostomia 0 Persistent 
(12)
- Persistent ANED 64/54 2 EA EA EA EA
Mean 3.6 3.2 76.5 31.4 176.3 1.3
Range 0–10 1–7 2.0–2.20 72.8–80.7 2.5–37.5 78–299 0–7.7
t postRT time (in months) from IMRT completion to appearance of late term reaction
NTR normal tissue reaction
PTD prescribed total dose
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respectively (manuscript submitted: disease outcome
related to GTV), is in evaluation as a first consequence of
these data.
Conclusion
IMRT in HNC, using the planning target volume and dose
concept as described, is a highly effective technique with
respect to tumor response and tolerance. SIB-IMRT is safe
and similarly well tolerated using either 2.11 or 2.2 Gy per
fraction to total doses of 66–70 Gy, although is not rec-
ommended for large tumors involving laryngeal struc-
tures.
There is clinical evidence for increased normal tissue tol-
erance following IMRT.
Methods
SIB schedules
SIB was performed in 109/115 patients; in the remaining
six cases a single dose-volume was painted.
Biomathematical consideration
In order to employ a slightly accelerated SIB schedule, 30
× 2.2 Gy per fraction, 5× per week, to 66 Gy in the high
dose area (PTV1), was chosen. This corresponds with the
BED of 35 × 2 Gyper session, 5x / week, to 70 Gy in terms
of early and late tolerance, assuming an alpha value of
0.35, and an alpha/beta ratio of 10 and 3, respectively
(BED for late effects 116.66, BED for early effects 70.1
Gy). Similarly, 2.11 Gy per fraction in 33 sessions to 69.6
Gy (PTV1) equals with 35 × 2 Gy to 70 Gy.
SIB-IMRT technique was performed using the following
schedules (5 fractions/week each):
2.2 Gy (PTV1) / 1.8 Gy (PTV2) to 66 Gy / 54 Gy, 5 frac-
tions/week (n = 33, SIB2.2)
2.11 Gy (PTV1)/1.64 Gy (PTV2) to 69.6 Gy / 54 Gy, 5 frac-
tions/week (n = 44, SIB2.11)
2.11 (PTV1) / 1.8 Gy (PTV2) to 63.3 / 54 Gy, 5 fractions/
week (n = 3, SIB2.11)
2.0 Gy (PTV1)/ 1.5–1.8 Gy (PTV2) to 60 – 70 / 52–56 Gy,
5–6 fractions/week (n = 34, SIB2.0)
In one patient with large necrotic nodes, a higher SIB dose
of 2.35 Gy per fraction to 75.2 Gy was delivered.
During the first 20 months, SIB-IMRT was performed with
SIB2.2 according to the RTOG study protocol H-0022.
Intermediate doses were individually defined to regions
considered at high risk for microscopic disease (PTV3,
doses ranging from 56 – 60 Gy).
In 7 / 33 patients subacute mucosal ulcers were observed.
As a consequence the decision was made to change the
Table 5: Disease outcome following IMRT in selected published series including the own study
Authors HNC cohorts N patients LC (%) NC (%) LRC DC (%) OAS (%) time point
Eisbruch et al 
[11]
oro/hypo/OC 133 94/77/60 3y
Dawson et al 
[1]
HNC w/o 
NPC
58 79 2y
Own study HNC w/o 
NPC
115 77 87 78 86 2y
Eisbruch et al 
[11]
dIMRT/
pIMRT
60/73 81/84 3y
Chao et al [4] dIMRT/
pIMRT
31/43 78/95 84/94 87 3y
Chao et al [5] dIMRT/
pIMRT
52/74 79/90 2y
own study dIMRT/
pIMRT
80/34 81/91 86/97 92/88 75/79 2y
Eisbruch et al 
[11]
oro 80 94 3y
Garden et al 
[in 6]
oro 80 (T1-2N0) 94 2y
De Arruda 17 oro 50 98 88 84 98 2y
Huang et al 
[in 6]
oro 41 94 89 91 89 2y
Own study oro 56 88 93 93 87 2y
LC local control; NC nodal control; LRC loco-regional control; DC distant control, OAS overall survival; oro oropharyngeal tumor; OC oral cavity 
tumor; NPC nasopharyngeal cancer; d/pIMRT defintive/postoperative IMRT.Page 8 of 15
(page number not for citation purposes)
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2.11 / 1.64 Gy per fraction to 63.3 – 69.6 / 54 Gy in 30 –
33 fractions (n = 47).
In all patients with tumor extension close to, or invading
the central nervous system (CNS), and in most patients
treated in a postoperative setting (n = 22/34), SIB2.0 was
prescribed. Doses to CNS structures never exceeded 2.0 Gy
per fraction and 70 Gy total dose, respectively.
Planning Computerized Tomography (Planning CT)
Planning CT (Somatom Plus 4, Siemens) was acquired
with 2 – 3 mm slice thickness and no interslice gap
throughout the whole sequentially acquired region of
interest. Patients were immobilized in a commercially
available thermoplastic mask with fixed head and shoul-
der. An integrated individually customized bite block.
In patients with postoperative irradiation gross tumor vol-
umes were drawn slice by slice in the planning CT, based
on diagnostic preoperative MRIs and PET-CTs, which were
available for all patients. In the majority of the definitively
An example of an IMRT isodose plan using simultaneously integrated boostFigure 6
An example of an IMRT isodose plan using simultaneously integrated boost. Depicted is an axial slice, 64 mm above the iso-
center of the plan. Contoured are PTV1 (69.6 Gy), PTV2 (60 Gy) and PTV3 (54 Gy), gross tumor volumes of the primary and 
macroscopic nodal disease, and normal structures (spinal cord, brain, parotid glands, anterior soft tissues, dorsal soft tissues). 
Note the well-spared spinal cord and parotid glands despite of bilateral nodal disease covered with high doses (nodal and pri-
mary gross tumor volumes included into the PTV1).Page 9 of 15
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formed.
Planning systems
Contouring and plan optimisation was performed on a
Varian Treatment Planning System (Eclipse®, Version
7.3.10, Varian Medical Systems, Hansen Way, Palo Alto
CA, 94304-1129)
Delineation of planning target volumes (PTVs)
Definitions
Gross Tumor Volume (GTV) with a margin of 10–15 mm
was included in the SIB volume (PTV1, 60 – 73 Gy)
Elective lymph node regions (PTV2, doses between 48 –
56 Gy):
In hypopharyngeal, central oropharyngeal and lateral
oropharyngeal tumors extending to midline structures,
An example of an IMRT isodose plan using simultaneously integrated boostFigure 7
An example of an IMRT isodose plan using simultaneously integrated boost. A more distal axial slice 12mm above the isocenterPage 10 of 15
(page number not for citation purposes)
Radiation Oncology 2006, 1:7 http://www.ro-journal.com/content/1/1/7bilateral lymph node regions level 2 – 5 and retropharyn-
geal nodes were included.
In lateral oropharynx tumors with bilateral nodal disease,
bilateral nodes level 2 – 5 were irradiated. In cases with
minimal contralateral nodal disease, level 2 – 5 excluding
the uppermost part of contralateral level 2 was included.
In nodally negative lateral T1-2 oropharynx tumors with-
out infiltration of the tongue and without palatinal infil-
tration crossing the midline, the elective node irradiation
was limited to the ipsilateral side. In T3/4 N0 or ispilateral
N1/2 situations, ipsilateral level 2 – 5 and contralateral
level 2 – 4 without the uppermost part were included,
respectively.
Submandibular nodes have been electively included only
in oral cavity tumors, or in tumors extending to the oral
cavity.
Dose constraints for normal tissues / organs at risk
(OARs) outside PTVs (see also Figures 6, 7, 8, 9)
Dose planning aimed at target doses of 60 – 70 Gy. Nor-
mal tissue doses were defined as follows:
Spinal cord/brain stem: maximum dose (Dmax) < 45 Gy,
mean dose (Dmean) < 35 Gy (spinal cord was contoured
with an at least 5 – 10 mm margin, > 10 mm at the ventral
aspect)
An example of an IMRT isodose plan using simultaneously integrated boostFigure 8
An example of an IMRT isodose plan using simultaneously integrated boost. A sagital view of a T2N2c staged hypopharyngeal 
cancer patient.Page 11 of 15
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degree possible without compromising target coverage:
Dmean < 26 Gy (outlined was the partial volume pro-
vided to be spared, no overlapping with PTVs; contouring
of the entire glands for analytic purposes)
Optic nerve outside PTV: Dmax < 50 Gy (optic nerve, ret-
ina and chiasm were contoured with a safety margin of 2
– 4 mm)
Chiasm: Dmax < 50 Gy
Retina outside PTV: Dmax < 45 Gy
Lacrimal glands: Dmax < 30 Gy
Brain: depending CNS vicinity to the tumor; Dmax ≤ 100
% of prescribed total dose of maximal 70 Gy, doses per
fraction of 1.8–2.0 Gy
An example of an IMRT isodose plan using simultaneously integrated boostFigure 9
An example of an IMRT isodose plan using simultaneously integrated boost. A coronar view of a T2N2c staged hypopharyngeal 
cancer patient.Page 12 of 15
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Oral cavity outside the PTV (contouring included the
mandible and maxillary bone and the oral vestibulum):
Dmean < 35 Gy
Nuchal tissue: Dmean < 45 Gy
Radiation
Irradiation was delivered by 6 MV photon beams on a Var-
ian linear accelerator with sliding window technique. The
technical solution of choice was a 5 field arrangements
('class solution') for most patients (n = 100); 6 fields were
applied in 7, 7 fields in 8 patients.
Patient alignment was checked before radiation by portal
imaging. Deviations of > 2 mm in nasopharyngeal cancers
and paranasal sinus tumors, of > 3 mm in all other
tumors, respectively, were corrected before treatment.
Three-dimensional position deviations from the digitally
reconstructed radiographs (DRRs) were compared and
calculated automatically (lateral and axial deviation, rota-
tion).
In the first 30 patients treated with IMRT at our institu-
tion, the accepted deviation was only 2 mm, independent
of the diagnosis. The position in all patients used to be
checked on a daily base for the entire treatment time and
was prospectively analysed.
Deviations of >2 mm occurred in 108 out of 241 evalu-
ated treatment sessions in patients (1:2.2 incorrect-to-cor-
rect position-ratio); 2/3 of all deviations that required a
pre-treatment correction were observed in patients with
large fields (when lymphatic pathways included in the
treatment volume).
Based on those data we went over to a) an accepted 3 mm
deviation for all patients except of those with sinonasal
and nasopharyngeal tumors, and b) to the following por-
tal vision check rhythm: daily checks only in the first three
treatment days, followed by a once to twice a week portal
vision check in all patients in whom positioning is ini-
tially found in the tolerated range. Every correction was
followed by another daily check period of three days.
The dose homogeneity within the PTV was aimed to be in
close accordance with the RTOG guidelines:
The dose was normalized to the mean dose in PTV1 which
corresponds, in the majority of cases, approximately to
the 95 % dose level in that volume.
- The prescription dose is the isodose which encompasses
at least 95 % of the PTV
- no more than 20 % of any PTV will receive >110 % of it's
prescribed dose
- no more than 1 % of PTV1 will receive < 93 % of its pre-
scribed dose
- no more than 1 % or 1 cc of the tissue outside the PTV
will receive > 110 % of the dose prescribed to the primary
PTV
Clinical quality assurance (QA)
- Follow up
During the course of irradiation, all patients were clini-
cally assessed at regular weekly intervals, and 2 weeks and
2 months after completion of treatment.
Approximately 6 weeks after completion, all patients were
also seen regularly in our joint clinics at the Department
of Head and Neck Surgery or Maxillofacial Surgery. Fur-
ther follow up visits were scheduled every 2 – 3 months in
the first 2 years, 3 – 4 monthly in the third year. When
clinical and/or endoscopic examination showed no evi-
dence of disease no radiological investigations were per-
formed; suspect findings were specified with CT-PET,
suspect lymph nodes by needle aspiration and/or biopsy,
respectively.
- QA with respect to posttreatment events
Isodose plans of all patients who experienced loco-
regional failure or grade 3/4 late term effects were
reviewed at the radiation planning work station, in order
to check local dose distributions at the regions of interest.
- QA with respect to quality of life (QoL)
Toxicity was assessed based on SOMA LENT and RTOG/
EORTC Radiation Morbidity Score. Both classifications
have been considered; for simplification, grade 3 or 4 late
reactions were termed 'grade 3/4' reactions.
Patients' QoL was prospectively assessed prior, during the
course of radiation, and 2 weeks, then 2, 6, 12, 18, and 24
months following IMRT (EORTC/RTOG-QLQ; results in
preparation).
StatView® program Version 4.5 was used for calculation of
Kaplan Meier actuarial survival curves. Mann-Whitney-U
test was used for comparison of volumes. P values < 0.05
were considered statistically significant.
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